VIVUS (NASDAQ: VVUS) and Mirna Therapeutics (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Earnings & Valuation

This table compares VIVUS and Mirna Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
VIVUS $133.40 million 0.79 $67.14 million $0.31 3.19
Mirna Therapeutics N/A N/A N/A ($9.59) -1.98

VIVUS has higher revenue and earnings than Mirna Therapeutics. Mirna Therapeutics is trading at a lower price-to-earnings ratio than VIVUS, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VIVUS and Mirna Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VIVUS -119.23% -457.88% -18.57%
Mirna Therapeutics N/A -44.70% -42.29%

Analyst Ratings

This is a summary of current recommendations for VIVUS and Mirna Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VIVUS 0 0 0 0 N/A
Mirna Therapeutics 0 2 1 0 2.33

Mirna Therapeutics has a consensus target price of $19.50, suggesting a potential upside of 2.55%. Given Mirna Therapeutics’ higher possible upside, analysts plainly believe Mirna Therapeutics is more favorable than VIVUS.

Risk and Volatility

VIVUS has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Mirna Therapeutics has a beta of 3.59, indicating that its share price is 259% more volatile than the S&P 500.

Institutional & Insider Ownership

35.8% of VIVUS shares are owned by institutional investors. 3.0% of VIVUS shares are owned by company insiders. Comparatively, 18.6% of Mirna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Mirna Therapeutics beats VIVUS on 6 of the 10 factors compared between the two stocks.

About VIVUS

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

About Mirna Therapeutics

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Receive News & Stock Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related stocks with our FREE daily email newsletter.